For the Inventor, By the Inventor

Enter assignee name

Bothell, WA, United States of America

Epoch Pharmaceuticals, Inc.

Calculating rank

USPTO Granted Patents = 21

Forward Citations = 1,069

Loading Chart...

Loading Chart...

21 inventors (with patents filed for the assignee):

Rich B Meyer, Jr (18 out of 30 patents)

Igor V Kutyavin (15 out of 49 patents)

Eugeny Alexander Lukhtanov (9 out of 51 patents)

4. Alexander A Gall (8 out of 47 patents)

5. Howard B Gamper (8 out of 10 patents)

6. Irina Aleksandrovna Afonina (5 out of 26 patents)

7. Michael W Reed (4 out of 33 patents)

8. Robert O Dempcy (2 out of 24 patents)

9. John C Tabone (2 out of 23 patents)

10. Joel Hedgpeth (2 out of 9 patents)

11. Evgeniy S Belousov (2 out of 6 patents)

12. Charles R Petrie (2 out of 26 patents)

13. Gerald D Hurst (2 out of 2 patents)

14. Yung-Chi Cheng (1 out of 61 patents)

15. Michael J Singer (1 out of 5 patents)

21 patents: Sort by Forward Citations

1. 6949367 - Modified oligonucleotides for mismatch discrimination (2005-09-27),

2. 6727356 - Fluorescent quenching detection reagents and methods (2004-04-27),

3. 6492346 - Hybridization and mismatch discrimination using oligonucleotides conjugated to minor groove binders (2002-12-10),

4. 6485906 - Oligonucleotides containing pyrazolo[3,4-d]pyrimidines for hybridization and mismatch discrimination (2002-11-26),

5. 6312953 - Bifunctional Crosslinking oligonucleotides adapted for linking to a target sequence of duplex DNA (2001-11-06),

6. 6312925 - Methods and compositions to facilitate D-loop formation by oligonucleotides (2001-11-06),

7. 6312894 - Hybridization and mismatch discrimination using oligonucleotides conjugated to minor groove binders (2001-11-06),

8. 6143877 - Oligonucleotides including pyrazolo[3,4-D]pyrimidine bases, bound in (2000-11-07),

9. 6136601 - Targeted mutagenesis in living cells using modified oligonucleotides (2000-10-24),

10. 6127121 - Oligonucleotides containing pyrazolo[3,4-D]pyrimidines for hybridization (2000-10-03),

11. 6084102 - Covalently linked oligonucleotide minor grove binder conjugates (2000-07-04),

12. 6072046 - Diaziridinyl-aryl and bis-[di(chloroethyl)amino]-aryl oligonucleotide (2000-06-06),

13. 5935830 - Targeted mutagenesis in living cells using modified oligonucleotides (1999-08-10),

14. 5912340 - Selective binding complementary oligonucleotides (1999-06-15),

15. 5849482 - Crosslinking oligonucleotides (1998-12-15),

Company Overview

Epoch Pharmaceuticals, Inc. is a biotechnology company based in Bothell, Washington, specializing in the development of innovative therapeutics for various medical conditions. The organization focuses on advancing drug discovery and formulation technologies, particularly in the fields of oncology and rare diseases. With a commitment to addressing unmet medical needs, Epoch leverages cutting-edge research to create effective treatment options, aiming to improve patient outcomes and enhance quality of life.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 27 2026

21 Patents

#25 in Bothell, WA

#336 in Washington

#15,719 in US

#30,018 in the World

Bothell, WA, United States of America

Epoch Pharmaceuticals, Inc.

Forward Citations = 1,069

21 inventors:

Rich B Meyer, Jr (18 out of 30 patents)

Igor V Kutyavin (15 out of 49 patents)

Eugeny Alexander Lukhtanov (9 out of 51 patents)

4. Alexander A Gall (8 out of 47 patents)

5. Howard B Gamper (8 out of 10 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Epoch Pharmaceuticals, Inc.. Retrieved from https://idiyas.com/company/epoch-pharmaceuticals

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…